NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$19.21 USD
-0.33 (-1.69%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $19.18 -0.03 (-0.16%) 7:58 PM ET
F Value F Growth F Momentum F VGM
NewAmsterdam Pharma Company N.V. (NAMS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$35.83 | $45.00 | $30.00 | 83.37% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for NewAmsterdam Pharma Company N.V. comes to $35.83. The forecasts range from a low of $30.00 to a high of $45.00. The average price target represents an increase of 83.37% from the last closing price of $19.54.
Analyst Price Targets (6 )
Broker Rating
NewAmsterdam Pharma Company N.V. currently has an average brokerage recommendation (ABR) of 1.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 87.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NAMS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.13 | 1.13 | 1.13 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/7/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/17/2024 | SVB Securities | Roanna Ruiz | Strong Buy | Strong Buy |
5/15/2024 | Cowen & Co. | Tyler Van Buren | Not Available | Strong Buy |
5/12/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
4/9/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
3/14/2024 | Scotiabank | George Farmer | Not Available | Strong Buy |
1/18/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.13 |
ABR (Last week) | 1.13 |
# of Recs in ABR | 8 |
Average Target Price | $35.83 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | -0.59 |